Adjuvant therapy for colorectal cancer continues to excite significant interest, particularly for “high-risk” patients in whom systemic 5-fluorouracil and leucovorin should be considered. However, intraportal 5-fluorouracil and intraperitoneal chemotherapy require further assessment. For rectal cancer, combined chemo- and radiotherapy have demonstrated survival advantages. In patients with advanced or recurrent disease, modification of 5-fluorouracil with folinic acid and locoregional infusion treatment have both demonstrated efficacy. In general immunotherapy, studies have so far proved disappointing for advanced colorectal cancer.